{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:46:31Z","timestamp":1787064391518,"version":"build-2736575974"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS097783"],"award-info":[{"award-number":["R01NS097783"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["K23NS080988"],"award-info":[{"award-number":["K23NS080988"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke"},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR000445"],"award-info":[{"award-number":["UL1TR000445"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Impulsivity is inherent to behavioral disorders such as substance abuse and binge eating. While the role of dopamine in impulse behavior is well established, \u03b3-aminobutyric acid (GABA) therapies have promise for the treatment of maladaptive behaviors. In Parkinson disease (PD), dopaminergic therapies can result in the development of impulsive and compulsive behaviors, and this clinical syndrome shares similar pathophysiology to that seen in addiction, substance abuse, and binge-eating disorders. We hypothesized that impulsive PD patients have a reduced thalamic GABAergic response to dopamine therapy. To test this hypothesis, we employed GABA magnetic resonance spectroscopy, D2-like receptor PET imaging, and clinical and quantitative measures of impulsivity in PD patients (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200933), before and after dopamine agonist administration. We find a blunted thalamic GABA response to dopamine agonists in patients with elevated impulsivity (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.027). These results emphasize how dopamine treatment differentially augments thalamic GABA concentrations, which may modify behavioral impulsivity.\n                  <\/jats:p>","DOI":"10.1038\/s41531-022-00298-8","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T06:12:26Z","timestamp":1649139146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dopamine-induced changes to thalamic GABA concentration in impulsive Parkinson disease patients"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9753-7071","authenticated-orcid":false,"given":"Paula","family":"Trujillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander K.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn R.","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3924-8455","authenticated-orcid":false,"given":"Megan","family":"Aumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0455-7450","authenticated-orcid":false,"given":"Yan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakmook","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manus J.","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel O.","family":"Claassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"key":"298_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/npp.2011.216","volume":"37","author":"G Addolorato","year":"2012","unstructured":"Addolorato, G., Leggio, L., Hopf, F. W., Diana, M. & Bonci, A. Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation. Neuropsychopharmacology 37, 163\u2013177 (2012).","journal-title":"Neuropsychopharmacology"},{"key":"298_CR2","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.2174\/138161210791516468","volume":"16","author":"F Caputo","year":"2010","unstructured":"Caputo, F. & Bernardi, M. Medications acting on the GABA system in the treatment of alcoholic patients. Curr. Pharm. Des. 16, 2118\u20132125 (2010).","journal-title":"Curr. Pharm. Des."},{"key":"298_CR3","doi-asserted-by":"publisher","first-page":"276.e13","DOI":"10.1016\/j.amjmed.2005.08.042","volume":"119","author":"G Addolorato","year":"2006","unstructured":"Addolorato, G. et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am. J. Med. 119, 276.e13 (2006).","journal-title":"Am. J. Med."},{"key":"298_CR4","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.3390\/jcm8111887","volume":"8","author":"Z Bimpisidis","year":"2019","unstructured":"Bimpisidis, Z. & Wall\u00e9n-Mackenzie, \u00c5. Neurocircuitry of reward and addiction: potential impact of dopamine\u2013glutamate co-release as future target in substance use disorder. J. Clin. Med. 8, 1887 (2019).","journal-title":"J. Clin. Med."},{"key":"298_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/brain\/awz007","volume":"142","author":"J Hammes","year":"2019","unstructured":"Hammes, J. et al. Dopamine metabolism of the nucleus accumbens and fronto-striatal connectivity modulate impulse control. Brain 142, 733\u2013743 (2019).","journal-title":"Brain"},{"key":"298_CR6","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/YCO.0000000000000544","volume":"32","author":"GKW Frank","year":"2019","unstructured":"Frank, G. K. W. Neuroimaging and eating disorders. Curr. Opin. Psychiatry 32, 478\u2013483 (2019).","journal-title":"Curr. Opin. Psychiatry"},{"key":"298_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/cercor\/10.3.220","volume":"10","author":"C Cavada","year":"2000","unstructured":"Cavada, C., Compa\u00f1y, T., Tejedor, J., Cruz-Rizzolo, R. J. & Reinoso-Su\u00e1rez, F. The anatomical connections of the macaque monkey orbitofrontal cortex. A review. Cereb. Cortex 10, 220\u2013242 (2000).","journal-title":"Cereb. Cortex"},{"key":"298_CR8","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/jnnp-2013-306787","volume":"85","author":"PJ Garcia-Ruiz","year":"2014","unstructured":"Garcia-Ruiz, P. J. et al. Impulse control disorder in patients with Parkinson\u2019s disease under dopamine agonist therapy: a multicentre study. J. Neurol. Neurosurg. Psychiatry 85, 840\u2013844 (2014).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"298_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/mds.26016","volume":"30","author":"D Weintraub","year":"2015","unstructured":"Weintraub, D., David, A. S., Evans, A. H., Grant, J. E. & Stacy, M. Clinical spectrum of impulse control disorders in Parkinson\u2019s disease. Mov. Disord 30, 121\u2013127 (2015).","journal-title":"Mov. Disord"},{"key":"298_CR10","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1212\/01.wnl.0000238503.20816.13","volume":"67","author":"V Voon","year":"2006","unstructured":"Voon, V. et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67, 1254\u20131257 (2006).","journal-title":"Neurology"},{"key":"298_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S0025-6196(11)60538-7","volume":"84","author":"JM Bostwick","year":"2009","unstructured":"Bostwick, J. M., Hecksel, K. A., Stevens, S. R., Bower, J. H. & Ahlskog, J. E. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin. Proc. 84, 310\u2013316 (2009).","journal-title":"Mayo Clin. Proc."},{"key":"298_CR12","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/WCO.0b013e32826fbc8f","volume":"20","author":"V Voon","year":"2007","unstructured":"Voon, V., Potenza, M. N. & Thomsen, T. Medication-related impulse control and repetitive behaviors in Parkinson\u2019s disease. Curr. Opin. Neurol. 20, 484\u2013492 (2007).","journal-title":"Curr. Opin. Neurol."},{"key":"298_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.psc.2020.02.001","volume":"43","author":"B Silva","year":"2020","unstructured":"Silva, B., Canas-Simi\u00e3o, H. & Cavanna, A. E. Neuropsychiatric aspects of impulse control disorders. Psychiatr. Clin. North Am. 43, 249\u2013262 (2020).","journal-title":"Psychiatr. Clin. North Am."},{"key":"298_CR14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/jnnp-2019-322453","volume":"91","author":"MJ Kelly","year":"2020","unstructured":"Kelly, M. J., Baig, F., Hu, M. T. M. & Okai, D. Spectrum of impulse control behaviours in Parkinson\u2019s disease: pathophysiology and management. J. Neurol., Neurosurg. Psychiatry 91, 703\u2013711 (2020).","journal-title":"J. Neurol., Neurosurg. Psychiatry"},{"key":"298_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/acn3.51016","volume":"7","author":"MA Aumann","year":"2020","unstructured":"Aumann, M. A. et al. Self\u2010reported rates of impulsivity in Parkinson\u2019s disease. Ann. Clin. Transl. Neurol. 7, 437\u2013448 (2020).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"298_CR16","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1212\/01.wnl.0000238503.20816.13","volume":"67","author":"V Voon","year":"2006","unstructured":"Voon, V. et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67, 1254\u20131257 (2006).","journal-title":"Neurology"},{"key":"298_CR17","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/WCO.0b013e32826fbc8f","volume":"20","author":"V Voon","year":"2007","unstructured":"Voon, V., Potenza, M. N. & Thomsen, T. Medication-related impulse control and repetitive behaviors in Parkinson\u2019s disease. Curr. Opin. Neurol. 20, 484\u2013492 (2007).","journal-title":"Curr. Opin. Neurol."},{"key":"298_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/mds.26016","volume":"30","author":"D Weintraub","year":"2015","unstructured":"Weintraub, D., David, A. S., Evans, A. H., Grant, J. E. & Stacy, M. Clinical spectrum of impulse control disorders in Parkinson\u2019s disease. Mov. Disord. 30, 121\u2013127 (2015).","journal-title":"Mov. Disord."},{"key":"298_CR19","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1093\/brain\/awr080","volume":"134","author":"V Voon","year":"2011","unstructured":"Voon, V. et al. Dopamine agonists and risk: impulse control disorders in Parkinson\u2019s disease. Brain 134, 1438\u20131446 (2011).","journal-title":"Brain"},{"key":"298_CR20","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1037\/a0023795","volume":"125","author":"DO Claassen","year":"2011","unstructured":"Claassen, D. O. et al. The risky business of dopamine agonists in Parkinson disease and impulse control disorders. Behav. Neurosci. 125, 492\u2013500 (2011).","journal-title":"Behav. Neurosci."},{"key":"298_CR21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/jnnp-2013-306787","volume":"85","author":"PJ Garcia-Ruiz","year":"2014","unstructured":"Garcia-Ruiz, P. J. et al. Impulse control disorder in patients with Parkinson\u2019s disease under dopamine agonist therapy: a multicentre study. J. Neurol. Neurosurg. Psychiatry 85, 841\u2013845 (2014).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"298_CR22","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00702-003-0027-5","volume":"110","author":"M Gerlach","year":"2003","unstructured":"Gerlach, M. et al. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J. Neural Transm. 110, 1119\u20131127 (2003).","journal-title":"J. Neural Transm."},{"key":"298_CR23","first-page":"81","volume":"33","author":"J Cornelius","year":"2010","unstructured":"Cornelius, J., Tippmann-Peikert, M., Slocumb, N., Frerichs, C. & Silber, M. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 33, 81\u201387 (2010).","journal-title":"Sleep"},{"key":"298_CR24","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/mds.27047","volume":"32","author":"DO Claassen","year":"2017","unstructured":"Claassen, D. O. et al. Mesocorticolimbic hemodynamic response in Parkinson\u2019s disease patients with compulsive behaviors. Mov. Disord. 32, 1574\u20131583 (2017).","journal-title":"Mov. Disord."},{"key":"298_CR25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/hbm.23860","volume":"39","author":"K Petersen","year":"2018","unstructured":"Petersen, K. et al. Ventral striatal network connectivity reflects reward learning and behavior in patients with Parkinson\u2019s disease. Hum. Brain Mapp. 39, 509\u2013521 (2018).","journal-title":"Hum. Brain Mapp."},{"key":"298_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cortex.2019.01.016","volume":"115","author":"P Trujillo","year":"2019","unstructured":"Trujillo, P. et al. Dopamine effects on frontal cortical blood flow and motor inhibition in Parkinson\u2019s disease. Cortex 115, 99\u2013111 (2019).","journal-title":"Cortex"},{"key":"298_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-444-63425-2.00001-5","volume":"211","author":"GW Arbuthnott","year":"2014","unstructured":"Arbuthnott, G. W. Thalamostriatal synapses\u2014another substrate for dopamine action? Brain Res. 211, 1\u201311 (2014).","journal-title":"Brain Res."},{"key":"298_CR28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1460-9568.2004.03842.x","volume":"21","author":"T Munsch","year":"2005","unstructured":"Munsch, T., Yanagawa, Y., Obata, K. & Pape, H.-C. Dopaminergic control of local interneuron activity in the thalamus. Eur. J. Neurosci. 21, 290\u2013294 (2005).","journal-title":"Eur. J. Neurosci."},{"key":"298_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.neuroimage.2015.06.066","volume":"120","author":"S Dharmadhikari","year":"2015","unstructured":"Dharmadhikari, S. et al. Striatal and thalamic GABA level concentrations play differential roles for the modulation of response selection processes by proprioceptive information. Neuroimage 120, 36\u201342 (2015).","journal-title":"Neuroimage"},{"key":"298_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3389\/fnhum.2014.00081","volume":"8","author":"RJ Buchanan","year":"2014","unstructured":"Buchanan, R. J. et al. Changes in GABA and glutamate concentrations during memory tasks in patients with Parkinson\u2019s disease undergoing DBS surgery. Front. Hum. Neurosci. 8, 81 (2014).","journal-title":"Front. Hum. Neurosci."},{"key":"298_CR31","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1152\/jn.00752.2014","volume":"113","author":"S Ding","year":"2015","unstructured":"Ding, S., Li, L. & Zhou, F. M. Nigral dopamine loss induces a global upregulation of presynaptic dopamine D1 receptor facilitation of the striatonigral GABAergic output. J. Neurophysiol. 113, 1697\u20131711 (2015).","journal-title":"J. Neurophysiol."},{"key":"298_CR32","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/sj.jcbfm.9600263","volume":"26","author":"F Hyder","year":"2006","unstructured":"Hyder, F. et al. Neuronal\u2013glial glucose oxidation and glutamatergic\u2013GABAergic function. J. Cereb. Blood Flow. Metab. 26, 865\u2013877 (2006).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"298_CR33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/jnr.20364","volume":"79","author":"Z Chen","year":"2005","unstructured":"Chen, Z., Silva, A. C., Yang, J. & Shen, J. Elevated endogenous GABA level correlates with decreased fMRI signals in the rat brain during acute inhibition of GABA transaminase. J. Neurosci. Res. 79, 383\u2013391 (2005).","journal-title":"J. Neurosci. Res."},{"key":"298_CR34","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1471-4159.1981.tb01608.x","volume":"36","author":"TL Perry","year":"1981","unstructured":"Perry, T. L., Hansen, S. & Gandham, S. S. Postmortem changes of amino compounds in human and rat brain. J. Neurochem. 36, 406\u2013412 (1981).","journal-title":"J. Neurochem."},{"key":"298_CR35","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/(SICI)1099-1492(199810)11:6<266::AID-NBM530>3.0.CO;2-J","volume":"11","author":"M Mescher","year":"1998","unstructured":"Mescher, M., Merkle, H., Kirsch, J., Garwood, M. & Gruetter, R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed. 11, 266\u2013272 (1998).","journal-title":"NMR Biomed."},{"key":"298_CR36","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1002\/mrm.21383","volume":"58","author":"RAE Edden","year":"2007","unstructured":"Edden, R. A. E. & Barker, P. B. Spatial effects in the detection of \u03b3-aminobutyric acid: Improved sensitivity at high fields using inner volume saturation. Magn. Reson. Med. 58, 1276\u20131282 (2007).","journal-title":"Magn. Reson. Med."},{"key":"298_CR37","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.mri.2006.11.026","volume":"25","author":"KW Waddell","year":"2007","unstructured":"Waddell, K. W., Avison, M. J., Joers, J. M. & Gore, J. C. A practical guide to robust detection of GABA in human brain by J-difference spectroscopy at 3 T using a standard volume coil. Magn. Reson. Imaging 25, 1032\u20131038 (2007).","journal-title":"Magn. Reson. Imaging"},{"key":"298_CR38","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41583-019-0189-2","volume":"20","author":"J Cox","year":"2019","unstructured":"Cox, J. & Witten, I. B. Striatal circuits for reward learning and decision-making. Nat. Rev. Neurosci. 20, 482\u2013494 (2019).","journal-title":"Nat. Rev. Neurosci."},{"key":"298_CR39","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/nn.3100","volume":"15","author":"AV Kravitz","year":"2012","unstructured":"Kravitz, A. V., Tye, L. D. & Kreitzer, A. C. Distinct roles for direct and indirect pathway striatal neurons in reinforcement. Nat. Neurosci. 15, 816\u2013818 (2012).","journal-title":"Nat. Neurosci."},{"key":"298_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0166-2236(95)80020-3","volume":"18","author":"RL Albin","year":"1995","unstructured":"Albin, R. L., Young, A. B. & Penney, J. B. The functional anatomy of disorders of the basal ganglia. Trends Neurosci. 18, 63\u201364 (1995).","journal-title":"Trends Neurosci."},{"key":"298_CR41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0079-6123(08)62678-3","volume":"85","author":"GE Alexander","year":"1990","unstructured":"Alexander, G. E., Crutcher, M. D. & Delong, M. R. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, \u2018prefrontal\u2019 and \u2018limbic\u2019 functions. Prog. Brain Res. 85, 119\u2013149 (1990).","journal-title":"Prog. Brain Res."},{"key":"298_CR42","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.tins.2007.03.006","volume":"30","author":"A Bj\u00f6rklund","year":"2007","unstructured":"Bj\u00f6rklund, A. & Dunnett, S. B. Dopamine neuron systems in the brain: an update. Trends Neurosci. 30, 194\u2013202 (2007).","journal-title":"Trends Neurosci."},{"key":"298_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.brainresrev.2007.05.004","volume":"56","author":"S Ikemoto","year":"2007","unstructured":"Ikemoto, S., Ikemoto, S. & Ikemoto, S. Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res. Rev. 56, 27\u201378 (2007).","journal-title":"Brain Res. Rev."},{"key":"298_CR44","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1172\/JCI18533","volume":"111","author":"ND Volkow","year":"2003","unstructured":"Volkow, N. D., Fowler, J. S. & Wang, G. J. The addicted human brain: insights from imaging studies. J. Clin. Investig. 111, 1444\u20131451 (2003).","journal-title":"J. Clin. Investig."},{"key":"298_CR45","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.brainres.2012.10.043","volume":"1490","author":"TR Stratford","year":"2013","unstructured":"Stratford, T. R. & Wirtshafter, D. Injections of muscimol into the paraventricular thalamic nucleus, but not mediodorsal thalamic nuclei, induce feeding in rats. Brain Res. 1490, 128\u2013133 (2013).","journal-title":"Brain Res."},{"key":"298_CR46","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3389\/fnbeh.2015.00321","volume":"9","author":"JW Seok","year":"2015","unstructured":"Seok, J. W. & Sohn, J. H. Neural substrates of sexual desire in individuals with problematic hypersexual behavior. Front. Behav. Neurosci. 9, 321 (2015).","journal-title":"Front. Behav. Neurosci."},{"key":"298_CR47","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.nicl.2018.02.010","volume":"18","author":"AJ Stark","year":"2018","unstructured":"Stark, A. J. et al. [18F]fallypride characterization of striatal and extrastriatal D2\/3receptors in Parkinson\u2019s disease. NeuroImage Clin. 18, 433\u2013442 (2018).","journal-title":"NeuroImage Clin."},{"key":"298_CR48","first-page":"3082","volume":"10","author":"AJ Stark","year":"1523","unstructured":"Stark, A. J. et al. Nigrostriatal and mesolimbic D2\/3 receptor expression in Parkinson\u2019s disease patients with compulsive reward-driven behaviors Nigrostriatal and mesolimbic D 2\/3 receptor expression in Parkinson\u2019s disease. C. Des. Res. Cite J. Neurosci. 10, 3082\u201317 (1523).","journal-title":"C. Des. Res. Cite J. Neurosci."},{"key":"298_CR49","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/sj.npp.1300336","volume":"29","author":"RW Rieck","year":"2004","unstructured":"Rieck, R. W., Ansari, M. S., Whetsell, W. O., Deutch, A. Y. & Kessler, R. M. Distribution of dopamine D2-like receptors in the human thalamus: autoradiographic and PET studies. Neuropsychopharmacology 29, 362\u2013372 (2004).","journal-title":"Neuropsychopharmacology"},{"key":"298_CR50","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hbm.24857","volume":"41","author":"AJM van Nuland","year":"2020","unstructured":"van Nuland, A. J. M. et al. GABAergic changes in the thalamocortical circuit in Parkinson\u2019s disease. Hum. Brain Mapp. 41, 1017\u20131029 (2020).","journal-title":"Hum. Brain Mapp."},{"key":"298_CR51","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","volume":"51","author":"WR Gibb","year":"1988","unstructured":"Gibb, W. R. & Lees, A. J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 51, 745\u2013752 (1988).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"298_CR52","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/mds.21198","volume":"22","author":"CG Goetz","year":"2007","unstructured":"Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov. Disord. 22, 41\u201347 (2007).","journal-title":"Mov. Disord."},{"key":"298_CR53","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.neurol.2015.03.008","volume":"171","author":"J Bourgeois-Marcotte","year":"2015","unstructured":"Bourgeois-Marcotte, J., Flamand-Roze, C., Denier, C. & Monetta, L. LAST-Q: adaptation et normalisation franco-qu\u00e9b\u00e9coises du Language Screening Test. Rev. Neurol. 171, 433\u2013436 (2015).","journal-title":"Rev. Neurol."},{"key":"298_CR54","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/014662167700100306","volume":"1","author":"LS Radloff","year":"1977","unstructured":"Radloff, L. S. The CES-D Scale. Appl. Psychol. Meas. 1, 385\u2013401 (1977).","journal-title":"Appl. Psychol. Meas."},{"key":"298_CR55","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov. Disord. 25, 2649\u20132653 (2010).","journal-title":"Mov. Disord."},{"key":"298_CR56","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1001\/archneur.64.8.1089","volume":"64","author":"V Voon","year":"2007","unstructured":"Voon, V. & Fox, S. H. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch. Neurol. 64, 1089 (2007).","journal-title":"Arch. Neurol."},{"key":"298_CR57","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/mds.26016","volume":"30","author":"D Weintraub","year":"2015","unstructured":"Weintraub, D., David, A. S., Evans, A. H., Grant, J. E. & Stacy, M. Clinical spectrum of impulse control disorders in Parkinson\u2019s disease. Mov. Disord. 30, 121\u2013127 (2015).","journal-title":"Mov. Disord."},{"key":"298_CR58","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/mds.24023","volume":"27","author":"D Weintraub","year":"2012","unstructured":"Weintraub, D. et al. Questionnaire for impulsive-compulsive disorders in Parkinson\u2019s Disease-Rating Scale. Mov. Disord. 27, 242\u2013247 (2012).","journal-title":"Mov. Disord."},{"key":"298_CR59","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1","volume":"51","author":"JH Patton","year":"1995","unstructured":"Patton, J. H., Stanford, M. S. & Barratt, E. S. Factor structure of the Barratt impulsiveness scale. J. Clin. Psychol. 51, 768\u2013774 (1995).","journal-title":"J. Clin. Psychol."},{"key":"298_CR60","unstructured":"Segal, D. L. In The Corsini Encyclopedia of Psychology (eds. Weiner, I. B. & Craighead, W.) 1\u20133 (American Cancer Society, 2010)."},{"key":"298_CR61","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/ana.410210409","volume":"21","author":"G Fabbrini","year":"1987","unstructured":"Fabbrini, G., Juncos, J., Mouradian, M. M., Serrati, C. & Chase, T. N. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson\u2019s disease. Ann. Neurol. 21, 370\u2013376 (1987).","journal-title":"Ann. Neurol."},{"key":"298_CR62","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/WNF.0b013e318176c505","volume":"32","author":"D Tompson","year":"2009","unstructured":"Tompson, D. & Oliver-Willwong, R. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-h prolonged release and ropinirole immediate release in patients with Parkinson\u2019s disease. Clin. Neuropharmacol. 32, 140\u2013148 (2009).","journal-title":"Clin. Neuropharmacol."},{"key":"298_CR63","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40290-021-00387-8","volume":"35","author":"KR Hay","year":"2021","unstructured":"Hay, K. R. et al. Symptoms of medication withdrawal in Parkinson\u2019s disease: considerations for informed consent in patient-oriented research. Pharm. Med. 35, 163\u2013167 (2021).","journal-title":"Pharm. Med."},{"key":"298_CR64","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.neuroimage.2012.12.004","volume":"86","author":"PG Mullins","year":"2014","unstructured":"Mullins, P. G. et al. Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA. Neuroimage 86, 43\u201352 (2014).","journal-title":"Neuroimage"},{"key":"298_CR65","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1002\/jmri.24478","volume":"40","author":"RAE Edden","year":"2014","unstructured":"Edden, R. A. E., Puts, N. A. J., Harris, A. D., Barker, P. B. & Evans, C. J. Gannet: A batch-processing tool for the quantitative analysis of gamma-aminobutyric acid-edited MR spectroscopy spectra. J. Magn. Reson. Imaging 40, 1445\u20131452 (2014).","journal-title":"J. Magn. Reson. Imaging"},{"key":"298_CR66","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.neuroimage.2017.08.073","volume":"162","author":"EC Porges","year":"2017","unstructured":"Porges, E. C. et al. Impact of tissue correction strategy on GABA-edited MRS findings. Neuroimage 162, 249\u2013256 (2017).","journal-title":"Neuroimage"},{"key":"298_CR67","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/jmri.24903","volume":"42","author":"AD Harris","year":"2015","unstructured":"Harris, A. D., Puts, N. A. J. & Edden, R. A. E. Tissue correction for GABA-edited MRS: considerations of voxel composition, tissue segmentation, and tissue relaxations. J. Magn. Reson. Imaging 42, 1431\u20131440 (2015).","journal-title":"J. Magn. Reson. Imaging"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00298-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00298-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00298-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T09:13:26Z","timestamp":1669281206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00298-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["298"],"URL":"https:\/\/doi.org\/10.1038\/s41531-022-00298-8","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,5]]},"assertion":[{"value":"23 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article. P.T. is a paid consultant for Alterity. M.J.D. is a paid consultant for Pfizer, Global Blood Therapeutics, Spark Therapeutics, LymphaTouch, and Alterity and has served on advisory boards for Novartis and bluebird bio. He receives research grant funding from the National Institutes of Health and Pfizer, research-related support from Philips Healthcare, and is the CEO of Biosight LLC which operates as a contracted Clinical Research Organization. D.O.C. receives research support from the Griffin Foundation, the Huntington\u2019s Disease Society of America, the National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Center for Complementary and Integrative Health, and Department of Defense; he received pharmaceutical grant support from AbbVie, Acadia, Biogen, BMS, Cerecour, Eli Lilly, Genetech\/Roche, PTC Therapeutics, Lundbeck, Jazz Pharmaceuticals, Teva Neuroscience, Spark, Wave Life Sciences, and Vaccinex; currently receives grant support from Genentech\/ Roche, AbbVie, Prilenia, Alterity, AbbVie, and CHDI, and he has served as a consultant to or on the advisory board of Acadia, Alterity, Adamas, Lundbeck, Neurocrine, Photopharmics, and Teva Neuroscience.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}